Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, M. William Audeh et al.|The Lancet|2010Cited by 1.6k
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation CarriersIgnacio Blanco, Miguel de la Hoya, Karoline Kuchenbaecker et al.|PLoS ONE|2015Cited by 39